{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:06:32Z","timestamp":1794373592154,"version":"4.9.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec id=\"ab-eoi250073-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>There are limited effective treatment options for diffuse conjunctival melanoma in situ (MIS), diffuse conjunctival intraepithelial neoplasia, and squamous cell carcinoma. There is a need for a more effective treatment with less ocular adverse effects than mitomycin C for MIS and 5-fluorouracil for ocular surface squamous neoplasia (OSSN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250073-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the outcomes of compounded imiquimod 5% in ophthalmic petrolatum-based ointment for diffuse conjunctival MIS or OSSN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250073-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was an interventional case series study at a tertiary referral center conducted from June 2024 to March 2025. Patients with a histological diagnosis of either conjunctival intraepithelial neoplasia (CIN), conjunctival squamous cell carcinoma, conjunctival MIS, or conjunctival melanoma with adjacent clinical primary acquired melanosis (PAM) were included in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250073-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Compounded imiquimod 5% ointment applied to the conjunctival surface 5 days per week for 12 weeks at a minimum (range, 12-15 weeks) along with a topical antibiotic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250073-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Histological resolution of MIS or OSSN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250073-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This case series included 5 patients (mean [SD] age, 77.4 [6] years; 4 female [80%]). At 12 weeks of treatment, there was complete clinical and histological response of CIN with moderate dysplasia, partial histological response (downgrade from squamous cell carcinoma to CIN with moderate dysplasia), and no histological recurrence of positive margins of squamous cell carcinoma excision. At 12 weeks of treatment, there was partial clinical response of diffuse MIS with mild persistence of epithelial pigmentation at the corneal limbus at the 7-o\u2019clock position; however, there was complete histological response in the areas of initial map biopsy. At 15 weeks of treatment, there was complete clinical and histological response of PAM. Of the 5 patients, all experienced ophthalmic adverse events only affecting the ocular surface and eyelids. All ocular surface adverse events resolved within 1 to 2 weeks of drug holiday or completing treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250073-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Study results suggest that, although definitive safety and efficacy cannot be determined across only 5 cases, compounded imiquimod 5% ointment may be a safe and effective approach to manage diffuse conjunctival MIS or OSSN. Longer-term follow-up with larger number of cases is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.4669","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:31:30Z","timestamp":1764174690000},"page":"42","source":"Crossref","is-referenced-by-count":2,"title":["Imiquimod Treatment for Conjunctival Melanoma In Situ or Ocular Surface Squamous Neoplasia"],"prefix":"10.1001","volume":"144","author":[{"given":"R. Christopher","family":"Bowen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Bryar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Department of Surgical Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Gerami","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"eoi250073r1","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archopht.1997.01100150810025","article-title":"Surgical management of conjunctival tumors\u2014the 1994 Lynn B. McMahan lecture.","volume":"115","author":"Shields","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"eoi250073r2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/ICO.0000000000000766","article-title":"Surgery vs interferon a-2b treatment strategies for ocular surface squamous neoplasia: a literature-based decision analysis.","volume":"35","author":"Siedlecki","year":"2016","journal-title":"Cornea"},{"issue":"5","key":"eoi250073r3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ophtha.2013.11.017","article-title":"Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.","volume":"121","author":"Nanji","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi250073r5","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.ophtha.2011.01.060","article-title":"Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences.","volume":"118","author":"Ditta","year":"2011","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi250073r6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/bjo.2005.086850","article-title":"Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.","volume":"90","author":"Khong","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"eoi250073r7","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s00417-004-1080-y","article-title":"Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years\u2019 experience.","volume":"243","author":"Kurli","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"eoi250073r8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2022.12.002","article-title":"Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: long-term follow-up study.","volume":"27","author":"Wylegala","year":"2023","journal-title":"Ocul Surf"},{"issue":"1","key":"eoi250073r9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10792-024-03182-x","article-title":"Efficacy of topical 5-fluorouracil in the management of ocular surface squamous neoplasia: a study of 101 eyes.","volume":"44","author":"Bakal","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"17","key":"eoi250073r10","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: the time is now.","volume":"41","author":"Long","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"eoi250073r12","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/archderm.141.4.510","article-title":"Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.","volume":"141","author":"Wolf","year":"2005","journal-title":"Arch Dermatol"},{"key":"eoi250073r13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action.","volume":"157","author":"Sch\u00f6n","year":"2007","journal-title":"Br J Dermatol"},{"issue":"6","key":"eoi250073r14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2015.02.008","article-title":"Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.","volume":"72","author":"Swetter","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"eoi250073r15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma.","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"33","key":"eoi250073r16","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1200\/JCO.2011.36.8829","article-title":"Treatment of locally recurrent mucosal melanoma with topical imiquimod.","volume":"29","author":"Smyth","year":"2011","journal-title":"J Clin Oncol"},{"key":"eoi250073r17","article-title":"Imiquimod treatment of vulvar melanoma in situ invading the urethra.","volume":"38","author":"Fuchs","year":"2021","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"eoi250073r18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/ijo.IJO_958_16","article-title":"Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area.","volume":"65","author":"Karabulut","year":"2017","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"eoi250073r19","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/IOP.0000000000000432","article-title":"Topical imiquimod in the treatment of conjunctival actinic keratosis.","volume":"33","author":"Rowlands","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"eoi250073r20","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.jcjo.2018.03.010","article-title":"Treatment of squamous cell carcinoma of the eyelid with imiquimod 5% cream.","volume":"54","author":"Singh","year":"2019","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"eoi250073r22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature.","volume":"151","author":"Kempen","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"13","key":"eoi250073r23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right\u2014interpreting zero numerators.","volume":"249","author":"Hanley","year":"1983","journal-title":"JAMA"},{"issue":"4","key":"eoi250073r24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1046\/j.1365-2133.2000.03787.x","article-title":"Imiquimod: a novel treatment for lentigo maligna.","volume":"143","author":"Ahmed","year":"2000","journal-title":"Br J Dermatol"},{"issue":"4","key":"eoi250073r25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/SAP.0b013e31816714c8","article-title":"Topical imiquimod therapy for lentigo maligna.","volume":"61","author":"Mahoney","year":"2008","journal-title":"Ann Plast Surg"},{"issue":"5","key":"eoi250073r26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archdermatol.2012.270","article-title":"A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.","volume":"148","author":"Hyde","year":"2012","journal-title":"Arch Dermatol"},{"issue":"12","key":"eoi250073r27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(06)70979-2","article-title":"Topical imiquimod: effectiveness in intraepithelial melanoma of oral mucosa.","volume":"7","author":"Spieth","year":"2006","journal-title":"Lancet Oncol"},{"issue":"10","key":"eoi250073r28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001219","article-title":"Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.","volume":"9","author":"Satish","year":"2021","journal-title":"J Immunother Cancer"},{"key":"eoi250073r4","unstructured":"ASHP. Interferon alfa-2b injection. Accessed March 19, 2025. https:\/\/www.ashp.org\/drug-shortages\/current-shortages\/drug-shortage-detail.aspx?id=724&loginreturnUrl=SSOCheckOnly"},{"key":"eoi250073r11","unstructured":"US Food and Drug Administration. Highlights of prescribing information Aldara. Accessed March 3, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/020723s028lbl.pdf"},{"key":"eoi250073r21","unstructured":"Bausch Health. Aldara imiquimod cream. Accessed March 2, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=0c3aed27-7b3f-442e-9f60-f2f5c672c85d&type=display"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2841802\/jamaophthalmology_bowen_2025_oi_250073_1767803508.60917.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:01:26Z","timestamp":1768492886000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2841802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.4669","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}